Internal medicine

Immunotherapy

Disease

Gastroesophageal Junction

Open label

Gastroenterology

Cancer

Oncology

Gastro-

Chemotherapy

Nivolumab

Reflux

Adenocarcinoma

Gastric adenocarcinoma

Clinical trial

Medicine

The Lancet

Nivolumab is the first PD-1 inhibitor to show superior OS, along with PFS benefit and an acceptable safety profile, in combination with chemotherapy versus chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma. Nivolumab plus chemotherapy represents a new standard first-line treatment for these patients.

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial